Novel imaging modalities in gynecologic cancer

Rebecca A. Brooks; Matthew A. Powell

doi:10.1007/s11912-009-0063-x

Novel imaging modalities in gynecologic cancer

Rebecca A. Brooks
, Matthew A. Powell

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Novel imaging modalities continue to emerge in medicine, and the advent of ¹⁸F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.

Original language	English
Pages (from-to)	466-472
Number of pages	7
Journal	Current oncology reports
Volume	11
Issue number	6
DOIs	https://doi.org/10.1007/s11912-009-0063-x
State	Published - Oct 26 2009

Access to Document

10.1007/s11912-009-0063-x

Cite this

@article{a2e5f731db184ae482f04c5e8352e5a9,

title = "Novel imaging modalities in gynecologic cancer",

abstract = "Novel imaging modalities continue to emerge in medicine, and the advent of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.",

author = "Brooks, \{Rebecca A.\} and Powell, \{Matthew A.\}",

year = "2009",

month = oct,

day = "26",

doi = "10.1007/s11912-009-0063-x",

language = "English",

volume = "11",

pages = "466--472",

journal = "Current oncology reports",

issn = "1523-3790",

number = "6",

}

TY - JOUR

T1 - Novel imaging modalities in gynecologic cancer

AU - Brooks, Rebecca A.

AU - Powell, Matthew A.

PY - 2009/10/26

Y1 - 2009/10/26

N2 - Novel imaging modalities continue to emerge in medicine, and the advent of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.

AB - Novel imaging modalities continue to emerge in medicine, and the advent of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.

UR - https://www.scopus.com/pages/publications/70350153115

U2 - 10.1007/s11912-009-0063-x

DO - 10.1007/s11912-009-0063-x

M3 - Review article

C2 - 19840524

AN - SCOPUS:70350153115

SN - 1523-3790

VL - 11

SP - 466

EP - 472

JO - Current oncology reports

JF - Current oncology reports

IS - 6

ER -

Novel imaging modalities in gynecologic cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this